Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's carvedilol 12.5
mg tablets to GSK's Coreg® 12.5 mg tablets following a single, oral 12.5 mg (1 x 12.5 mg)
dose administered under fasting conditions.